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Abstract Hypertension is a complex trait with deranged
autonomic control of the circulation. The sympathoadrenal
system exerts minute-to-minute control over cardiac output
and vascular tone. Catecholamine storage vesicles (or
chromaffin granules) of the adrenal medulla contain
remarkably high concentrations of chromogranins/secretog-
ranins (or “granins”), catecholamines, neuropeptide Y,
adenosine triphosphate (ATP), and Ca2+. Within secretory
granules, granins are co-stored with catecholamine neuro-
transmitters and co-released upon stimulation of the
regulated secretory pathway. The principal granin family
members, chromogranin A (CHGA), chromogranin B
(CHGB), and secretogranin II (SCG2), may have evolved
from shared ancestral exons by gene duplication. This
article reviews human genetic variation at loci encoding the
major granins and probes the effects of such polymor-
phisms on blood pressure, using twin pairs to probe
heritability and individuals with the most extreme blood
pressure values in the population to study hypertension.
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Introduction: The Sympathoadrenal System
and Granins
The sympathoadrenal system exerts minute-to-minute con-
trol over cardiac output and vascular tone. Genes governing
catecholaminergic processes may play a role in the
development of hypertension. Catecholamine storage
vesicles (or chromaffin granules) of the adrenal medulla
(Fig. 1) contain remarkably high concentrations of chro-
mogranins/secretogranins (“granins”), neuropeptide Y
(NPY), catecholamines, adenosine triphosphate (ATP), and
Ca2+. Within the vesicle core, granins bind catecholamines
and ATP, to stabilize the core osmotically [1, 2]. When the
major granin, chromogranin A (CHGA), is depleted by
gene targeting, adrenal chromaffin granules are reduced in
number, size, and electron density, and transmitter secretion
from the regulated pathway is disrupted [3]. Granins also
bind to the inner aspect of the vesicle membrane, where
they may influence the release of calcium from secretory
granules to the cytosolic exocytotic machinery through the
inositol 1,4,5-trisphosphate receptor/Ca2+ channel [4].
CHGA, chromogranin B (CHGB), and secretogranin II
(SCG2) are paralogous genes that likely arose by gene
duplication within the vertebrate lineage [5], suggesting
closely related cellular and physiological functions. Heter-
ologous expression of any one of the three “granins” is
sufficient to induce secretory granules and regulated
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secretion in cells that otherwise lack both [6–8], and depletion
of endogenous CHGA impairs formation of chromaffin
granules in PC12 chromaffin cells [3]. Within secretory
granules, granins are co-stored with catecholamine neuro-
transmitters and are co-released upon stimulation of regulated
secretion. Information on chromosomal positions, genomic
structure, cDNA, and proteins encoded by the three genes is
displayed in Table 1.
Proteolytic cleavage of granins at dibasic sites generates an
array of bioactive peptides within secretory vesicles. In
aggregate, these peptides have physiological effects on
cardiovascular, endocrine, metabolic, and immune systems
through both direct and indirect participation of the sympathetic
nervous system [9]. CHGA is a pro-hormone that gives rise to
at least four biologically active fragments: the dysglycemic
peptide pancreastatin [10, 11]; the antimicrobial peptide
chromacin [12]; the amino-terminal vasodilator vasostatin
[13]; and the catecholamine release inhibitor catestatin [14,
15]. As a pro-protein, CHGB is cleaved to biologically active
fragments including “GAWK” [16, 17] (bovine Chgb398–464,
human CHGB420–493), “CCB” [16] (human CHGB597–656),
“PE-11” [18] (rat Chgb532–542, human CHGB536–545), and the
endogenous antimicrobial/bacteriolytic peptides chrombacin
[19] (bovine Chgb564–626, human CHGB597–657) and secreto-
lytin [20] (bovine Chgb614–626, human CHGB647–657). SCG2
is the precursor of the 33–amino acid peptide secretoneurin
(SN, human SCG2165–187), which modulates neurotransmis-
sion and inflammatory responses and may be involved in
neuronal differentiation [21].
This review first considers the cellular and physiological
mechanisms of granin action that relate to sympathoadrenal
regulation, and then reviews recent findings on associations
Fig. 1 Intracellular and extracellular chromogranin/secretogranin
actions. Chromaffin granule transmitter storage and exocytotic release
are depicted, with secretion in response to the preganglionic trans-
mitters acetylcholine (Ach) or pituitary adenylyl cyclase activating
polypeptide (PACAP). Catestatin, the endogenous nicotinic choliner-
gic antagonist (ganglionic-blocking) peptide fragment of CHGA,
inhibits the principal physiological trigger of chromaffin cell secretory
stimulation: the nicotinic cholinergic pathway. ATP—adenosine
triphosphate; CHGA—chromogranin A; CHGB—chromogranin B;
nAchR—nicotinic cholinergic receptor; NPY—neuropeptide Y;
PAC1R—PACAP type 1 receptor; SCG2—secretogranin II. (Adapted
from Mahapatra et al. [1])
Table 1 Genomic structure of classic/major human chromogranin/secretogranins: CHGA, CHGB, and SCG2
Gene Chromosome Chromosomal position Genomic size (bp) cDNA (bp) Exons Amino acids Signal peptide Molecular weight (Da)
CHGA 14q32 93389445–93401636 12,192 2,079 8 457 1–18 48,918
CHGB 20p12.3 5891974–5906003 14,030 2,666 5 677 1–20 76,326
SCG2 2q36.1 224461660–224467121 5,462 2,490 2 617 1–27 70,810
Bp base pairs; Da Daltons
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of genetic variants in these genes with blood pressure and
intermediate phenotypes that may underlie susceptibility to
hypertension.
Granin Secretion and Hypertension
CHGA
Basal plasma CHGA concentration is correlated with sympa-
thetic tone [22, 23], and studies in twins indicate that the
basal level is highly heritable [24]. As compared with age-
matched normotensive controls, patients with essential
hypertension have increased plasma CHGA and an increased
release of stored CHGA in response to adrenal medullary
stimulation by insulin-evoked hypoglycemia [24]. The
dysglycemic CHGA fragment pancreastatin is also elevated
in patients with essential hypertension with or without
obesity [25, 26]; its actions may therefore contribute to the
insulin resistance that often accompanies the condition.
Catestatin, the CHGA–derived peptide that inhibits catechol-
amine release, is decreased in patients with essential
hypertension and even in normotensive subjects with a
family history of hypertension [27]. Moreover, people with
such a family history have increased epinephrine secretion in
addition to diminished catestatin, suggesting an inhibitory
effect of catestatin on chromaffin cells in vivo. Low catestatin
levels also predict augmented adrenergic response to
stressors, suggesting that reduction in catestatin increases
risk of hypertension [27]. The catestatin Gly364Ser variant
causes profound changes in human autonomic activity, both
parasympathetic and sympathetic, and seems to reduce risk
of developing hypertension, especially in men. A model for
catestatin action in the baroreceptor center of the nucleus of
the tractus solitarius accounts for these actions [28].
Consistent with these findings in humans, expression of the
Chga gene was observed to be significantly higher in adrenal
glands of rat and mouse models of genetic hypertension [29–
31], supporting the phenotypic association between elevated
CHGA and essential hypertension.
CHGB
Expression of CHGB may mark the action of still poorly
characterized trans-quantitative trait loci influencing exocy-
totic sympathoadrenal activity [32, 33]. Like CHGA, CHGB
may be differentially expressed in rodent models of genetic
hypertension [29, 30] and acquired hypertension [34], further
suggesting augmented sympathoadrenal activity in the
pathogenesis of these syndromes. CHGB may thereby give
rise to early, pathogenic “intermediate phenotypes” [35] for
exploration of sympathoadrenal activity in human essential
hypertension.
SCG2
The secretoneurin peptide derived from SCG2 (human
SCG2165–187) stimulates migration and proliferation of
vascular smooth muscle cells [21] and acts as an endothelial
cytokine to promote angiogenesis and vasculogenesis [30,
36], providing a direct link to vascular development and
remodeling and a potential model for its involvement in
autonomic phenotypes.
Population Samples and Traits for Genetic Studies
of Hypertension: Mechanism and Risk
Twin and Sibling Pairs
Applying a classic twin design in the search for trait-
associated polymorphisms [37], multiple autonomic pheno-
types were measured in twin pairs, permitting estimation of
trait heritability and definition of effects of particular
genetic variants on “intermediate” (early, pathogenic)
phenotypes; simultaneous documentation of heritability
and association lends internal validation to the approach.
Twins in such allelic/haplotype association studies were
self-identified as being of European (white) ancestry, to
minimize effects of population stratification.
Blood Pressure Change During Cold Stress: Heritable
“Intermediate” Phenotype of Hypertension
Because systemic hypertension may result from the cumula-
tive effects of transient adverse blood pressure (BP) responses
to environmental stress in genetically predisposed individuals
[38], we probed the BP response to environmental stress,
using cold as a systematic stimulus in a series of predom-
inantly normotensive twin pairs. Stress BP increments were
significantly heritable (h2=32±8%, P=0.0003 for change in
diastolic BP [DBP]; h2=23±9%, P=0.0098 for change in
systolic BP [SBP]), as estimated by twin pair variance
components [39].
Population Sample With Extreme BP Values: A Statistically
Powerful Sample for Association Studies of Hypertension
To pursue the genetic involvement in established essential
hypertension, we developed a powerful resource in the form
of a population-based sample consisting of individuals with
extremely high and low BPs [40]. From a primary care
practice sample of over 53,000 people, we ascertained more
than 1,000 individuals from the upper and lower 5th
percentiles of the population BP distribution, matched for
age, gender, and ethnicity [41].
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CHGA Genetic Variants and Blood Pressure
Open Reading Frame
During resequencing, three variants were discovered in the
catestatin region, the most common of which was Gly364Ser,
at ~3.1% of the initial ~360 chromosomes resequenced [42]. In
cultured hippocampal neurons, wild-type human catestatin
(SSMKLSFRARAYG364FRGPGPQL) inhibited nicotinic
cholinergic-stimulated catecholamine release completely (to
0.3±2.8% of control) at 10 μmol/L. The same dose of the
364Ser variant (SSMKLSFRARAYS364FRGPGPQL)
inhibited catecholamine release with substantially reduced
potency: 35.7±3.1% of control secretion persisted [28].
Carriers of 364Ser had diminished renal norepinephrine
excretion (by ~26%; P=0.047) and epinephrine excretion
(by ~34%; P=0.003); plasma norepinephrine also declined
by ~36% (P=0.019), though plasma epinephrine was un-
changed [28]. Gly/Ser heterozygotes displayed increased
baroreceptor slope during upward deflections (by ~47%) and
downward deflections (by ~44%), increased cardiac parasym-
pathetic index (by ~2.4-fold), and decreased cardiac sympa-
thetic index (by ~26%). The 364Ser variant was associated
with lower diastolic blood pressure in two independent/
confirmatory groups of patients with hypertension (UCSD
unrelated, n=489; population with blood pressure extreme
values, n=1361); genotype groups differed by ∼5–6 mm Hg,
and the polymorphism accounted for ∼1.8% of population
diastolic blood pressure variance, although a significant gene-
by-sex interaction existed, with an predominant effect in men.
Promoter: CHGA Promoter Haplotype Effects on Stress
Traits
Five tightly linked common promoter variants—at positions C-
1014T (rs9658630), G-988T (rs9658631), G-462A
(rs9658634), C-415T (rs9658635), and A-89C (rs7159323)—
were investigated in a study of 112 phenotyped twin pairs
(2n=224 individuals), and haplotypes were inferred with the
HAP algorithm, a method for haplotype resolution from
genotype data [43]. The three most common haplotypes,
TTGTC (Hap-A, 56.9%), CGATA (Hap-B, 23.0%), and
TTGCC (Hap-C, 16.5%), accounted for more than 95% of
all haplotypes. Diploid haplotypic variation in the region
affected both the change in DBP (P=0.0222) and the final
DBP (P=0.0167) during cold stress [44•]. Homozygosity for
Hap-B (CGATA/CGATA) seemed to blunt both the change in
DBP and the final DBP, whereas Hap-A/Hap-B heterozygos-
ity (TTGTC/CGATA) was associated with the greatest values
of both the change in DBP and the final DBP. The more
extreme trait values for heterozygotes (as compared with
either homozygote class) suggested the phenomenon of
molecular heterosis [45].
CHGA 3′-UTR Variant C+87T (rs7610) and Dichotomous
(Hypertension) as well as Continuous (mm Hg) BP Traits
Table 2a indicates the C+87T genotype effect in men (P=
0.004) and lack of effect in women (P=0.262). To focus on
the role of the minor (T) allele, we combined the minor allele
homozygote (T/T) with heterozygote (C/T) categories, and
compared them with C/C (major allele) homozygotes. The C
allele displayed a significant effect on blood pressure in men
but not in women [46•].
Table 2b shows the effects of C+87T on SBP and DBP as
continuous traits (in mm Hg). Even though these individuals
were ascertained from the population by a DBP criterion [41],
those who were hypertensive exhibited elevations of both
DBP and SBP, and there were significant effects of C+87T
genotype on both SBP (P=0.028) and DBP (P=0.037).
Likewise, there were significant genotype-by-sex interactions
on both SBP (P=0.015) and DBP (P=0.010). In men, BP
differences between homozygote (C/C, T/T) classes were
substantial: ∼12 mm Hg for SBP and ∼9 mm Hg for DBP. By
ANOVA (adjusted) R2 in men, C+87T accounted for ∼1.9%
of the population variance in SBP (or ∼13.7 mm Hg),
and ∼1.2% of the variance for DBP (or ∼5.8 mm Hg). In
women, C+87T did not affect either SBP or DBP.
CHGB and Blood Pressure
CHGB Promoter Variants A-296C and A-261T: Implications
for Hypertension
There are two common single nucleotide polymorphisms
(SNPs) in the proximal promoter of human CHGB: A-296C
(rs236140) and A-261T (rs236141). Promoter haplotype
effects upon BP in the population were highly significant
(Fig. 2) [47•]. Chromosome-based haplotype analysis on
individuals dichotomized into two groups (higher versus
lower BP) indicated that individuals with the less common
AT or CA haplotypes had a strong tendency to be
hypertensive (OR=4.898 for AT haplotype, P=3.19E-11;
OR=3.84 for CA haplotype, P=3.64E-10). People with the
more common haplotype CT had a strong tendency to be
normotensive (OR=0.637; 95% CI, 0.524–0.773; P=
4.64E-6). The most common haplotype, AA, had no effect
on BP status. The overall effect of CHGB haplotypes on BP
status was substantial, as shown on Fig. 2, whether
analyzed by chromosome/haplotype (global χ2=93.9, P=
3.16E-20) (left panel) or by diploid haplotype pairs (global
χ2=75.0, P=4.92E-13) (right panel).
We also studied the quantitative trait effects (SBP and DBP
in mm Hg) of CHGB haplotypes, and found substantial
predictions for both SBP and DBP. With increasing copy
number (0→1→2) of haplotype AT, SBP increased
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by ∼29 mm Hg (P=0.0002), whereas DBP increased
by ∼21 mm Hg (P=1.59E-5), each in additive fashion. With
increasing copy number of haplotype CA, SBP increased
by ∼13 mm Hg (P=0.005) and DBP increased
by ∼12 mm Hg (P=8.49E-6). With increasing copy number
of haplotype CT, SBP decreased by ∼11 mm Hg (P=0.0045),
with a parallel decrease in DBP by ∼7 mm Hg (P=0.011).
When we adjusted BP values for the effects of antihyperten-
sive medications in treated hypertensives [48], the haplotype
effects on SBP/DBP persisted or increased: AT, P=4.1E-5/
P=6.83E-6; CA, P=0.008/P=2.04E-5; CT, P=0.002/
P=0.008.
Promoter polymorphisms A-296C/A-261T interacted
nonadditively to influence SBP and DBP (P=1.15E-6/P=
Table 2 CHGA 3′-UTR common variant C+87T and BP. Effect of the T allele on blood pressure status and valuesa
Sex Genotype
a. CHGA C+87T genotype frequencies and BP status (dichotomized)b
High BP, n Low BP, n P (2-sided)
Male C/C 156 107
C/T or T/T 95 112 0.004
Female C/C 112 170
C/T or T/T 119 148 0.262
b. CHGA C+87T genotype and BP as a continuous traitc
SBP (mm Hg) DBP (mm Hg)
Male C/C 137.2±1.6 83.7±1.3
C/T or T/T 131.2±1.8 77.6±1.5
Male ANOVA P value 0.016 0.003
Female C/C 123.8±1.7 71.8±1.2
C/T or T/T 126.9±1.7 73.8±1.3
Female ANOVA P value 0.206 0.272
Reprinted from Journal of the American College of Cardiology, Vol. 52. Chen Y, Rao F, Rodriguez-Flores JL, et al.: Naturally occurring human
genetic variation in the 3′-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and
hypertension in a sex-dependent fashion; Pages 1468–1481, Copyright 2008, with permission from Elsevier
ANOVA analysis of variance; BP blood pressure; DBP diastolic blood pressure; SBP systolic blood pressure; UTR untranslated region
a Subjects are grouped by absence (C/C) or presence (T/T or C/T) of the T (minor) allele
b Results evaluated by chi-square test
c Allelic association (presence or absence of the T allele) evaluated by univariate ANOVA
  
Fig. 2 Prediction of blood pressure (BP) status by CHGB promoter
haplotypes in a population (of European ancestry) with BP extremes.
Haplotypes (or haplotype pairs) are ordered by rank of association
with elevated BP. Left: Haplotype (chromosome) effects. Right:
Haplotype pair (diploid haplotype) effects. The two most common
haplotypes (AA and CT) are more frequent in individuals with lower
BP, whereas the two less common haplotypes (CA and AT) are more
frequent in those with higher BP. CHGB—chromogranin B; HT—
hypertensive; NT—normotensive. (Adapted from Zhang et al. [47•])
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1.07E-10). On a background of A-296C major allele
homozygosity (A/A), the A-261T major (A) allele lowered
SBP/DBP by ∼27/∼22 mm Hg, whereas on a background
of A-296C minor allele homozygosity (C/C), the A-261T
major (A) allele elevated SBP/DBP by ∼21/∼18 mm Hg.
When treatment-adjusted BPs [48] were analyzed, the
interactions increased or persisted: SBP/DBP, P=4.41E-7/
P=1.08E-10. The A-296C-by-A-261T (SNP-by-SNP) in-
teraction was confirmed on analyses of the dichotomous BP
trait (higher vs lower): P=3.71E-15.
SBP/DBP values stratified by CHGB promoter haplotypes
were, in rank order: CT<AA<<CA<AT (SBP/DBP, P=
6.16E-8/P=5.18E-12). On ANOVA, CHGB promoter genet-
ic variation accounted for ∼2.3% of SBP variance and ∼3.4%
of DBP variance in this primary care population.
Parallel Effects of Human CHGB Promoter Haplotypes
In Vivo and in Cells
To probe the functional significance of the two common
promoter variants for transcriptional efficiency, we inserted
each of the four haplotypes (across A-296C and A-261A) into
the luciferase reporter plasmid pGL3-Basic. After transfection
into rat chromaffin (PC12) cells, these four haplotypes yielded
substantially different luciferase reporter activity. Site-specific
analysis of reporter activity showed that both A-296C and A-
261T have context-dependent actions. The transcriptional
strengths of combinations of A-296C and A-261T were
AT>CT>AA>CT (P=8.46E-07). By two-way ANOVA,
overall F=107.2, P=8.46E-07; A-296C, P=2.09E-05; A-
261T, P=0.064; 296-by-261 interaction, P=3.07E-07. The
four promoter haplotypes displayed the same rank order for
effects on BP in vivo and for luciferase reporter activity in
chromaffin cells.
“Intermediate” Traits: Association of CHGB Promoter
Variants A-296C and A-261T
In 163 white twin pairs who were predominantly (∼90%)
normotensive, the DBP response to environmental (cold)
stress was substantially heritable (h2=32±8%, P=0.0003)
[49]. CHGB promoter individual genotypes A-296C (A>C,
P=0.0237) and A-261T (A>T, P=0.037) predicted the
change in DBP in the cold stress test. Because of the
modest sample size (2n=326 chromosomes), we observed
only five examples of the CA haplotype and one of the AT
haplotype, so analyses could only be performed for
haplotypes AA and CT. Consistent with basal BP in white
BP extremes, the CT haplotype decreased the change in
DBP in response to stress, whereas the AA haplotype
increased it; thus, the rank order of effects of the haplotypes
on BP was preserved in twins (AA>CT), though the effects
of the more prominent BP-increasing haplotypes (CA, AT)
could not be quantified in this predominantly normotensive
sample.
CHGB 3′-UTR Common Variant C+84A (rs2821),
Isoprostane, and Hypertension
Isoprostane marks oxidative stress, and elevated isoprostane
excretion may be involved in cardiovascular target organ
damage. Urinary isoprostane excretion was substantially
heritable in twin pairs (h2=65.8±4.3%), and the isoprostane
trait aggregated with multiple traits (CHGB, catecholamines,
autonomic/baroreceptor sensitivity, and renal function),
including several features of the metabolic syndrome (body
mass index, insulin resistance, dyslipidemia). Isoprostane
excretion also paralleled systemic hypertension. A common
variant in the 3′-untranslated region (UTR) of CHGB
(C+84A, rs2821) associated with plasma CHGB and
isoprostane excretion. C+84A disrupted an A/U-rich mRNA
stability element, and in transfected luciferase/3′-UTR
plasmids, the C+84 and +84A alleles differed markedly in
reporter expression in chromaffin and neuroblastoma cells;
site-directed mutagenesis confirmed the importance of this
variant within the context of the A/U-rich motif [50•].
SCG2 and Blood Pressure
SCG2: A Functional Intronic Variant (G736A, rs1017448,
intron-1) Is Associated with Hypertension
At systematic polymorphism discovery at the SCG2 locus,
BP associations maximized at variant G736A (rs1017448)
in the sole intron; G736A is common (at ∼30.5%) only in
African Americans, and the minor allele A seemed to be
ancestral [51]. This SNP was investigated in five different
cohorts. G736A was associated with blood pressure in
African Americans from the University of California, San
Diego (UCSD) (n=383, P=0.0049), with the ancestral
allele (A) predicting increased risk for hypertension.
Significant association was observed in a second cohort of
unrelated African Americans from metropolitan San Diego
(n=465) for both recessive (P=0.022) and dominant (P=
0.0098) models. Taking the two case-control studies as
independent observations supports P∼10−4 for either
dominant or recessive models. In African American
families from the GenNet network of the NHLBI Family
Blood Pressure Program (n=781), analysis shows associa-
tion of G736A with SBP (FBAT, P=0.032 under an
additive model) and pulse pressure (FBAT, P=0.0074
additive model; P=0.0076 for dominant or recessive
models), though not with hypertension diagnosis as a
dichotomous trait. However, two population samples with
extreme BPs—a Nigerian sample (n=370) and a European
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American sample (n=1,315)—showed no significant asso-
ciations, although the minor allele frequency among
European Americans was too low to be sufficiently
informative; indeed, we observed no minor allele homo-
zygotes among those 1,315 individuals.
Thus all three African American cohorts showed
significant association of the 736A allele with elevated
blood pressure or hypertension. A meta-analysis was
performed of unrelated individuals from all five cohorts,
and this analysis showed significant associations in both
additive models (P=0.017) and dominant models (P=
0.028), which survived correction for covariates.
Paired-like homeobox transcription factors PHOX2A
(ARIX) and PHOX2B were identified by oligonucleotide
affinity chromatography and mass spectrometry as potential
transactivating factors across the G736A motif; this finding
was confirmed by chromatin immunoprecipitation. Each of
these transcription factors preferentially binds the risk
allele, both in vitro and in vivo [51]. PHOX2A and
PHOX2B play roles in autonomic nervous system function;
these paralogous genes are expressed in a largely over-
lapping pattern during development [52], but genetic
studies point to unique requirements for each factor in vivo.
Hypertension Consequences: The Kidney
CHGA and Microalbumin Excretion
Urinary albumin excretion is a risk factor for adverse
cardiovascular events, and even albumin excretion values less
than those typically cited as constituting microalbuminuria or
incipient nephropathy may signal cardiovascular risk. Urinary
excretions of albumin and catecholamines were highly
heritable in twin pairs, and their parallel suggests adrenergic
mediation of early glomerular permeability alterations [53];
indeed, the heritability of albumin excretion was h2=45.2±
7.4% (P=2×10−7). In the same study, we found that albumin
excretion associated with polymorphisms at multiple points
in the adrenergic pathway: catecholamine biosynthesis,
catabolism, storage/release (CHGA), receptor targets, and
postreceptor signal transduction. At CHGA, associations
were found not only for haplotypes spanning the locus, but
also for functional catestatin variant Gly364Ser. Thus
interindividual variability in albumin excretion is controlled
in substantial part by genetic variation in the adrenergic
pathway, including common, naturally occurring polymor-
phism at the CHGA locus.
CHGA Genetic Variation and Hypertensive Renal Disease
Among blacks, we studied common genetic variants
spanning the CHGA locus in two independent case-control
studies of hypertensive end-stage renal disease (ESRD),
comprising 58 cases and 150 control subjects. Two
haplotypes were significantly more frequent among patients
with hypertensive ESRD: 1) in the promoter (5′) region, G-
462A (rs9658634) →T-415C (rs9658635) →C-89A
(rs7159323), haplotype ATC (adjusted OR=2.65; P=
0.037); and 2) at the 3′-end, C11825T (3′-UTR, C+87T;
rs7610) →G12602C (rs875395), haplotype TC (adjusted
OR=2.73, P=0.0196). Circulating levels of catestatin were
lower among those with hypertensive ESRD than among
controls, an unexpected finding given that peptide levels
are usually elevated in ESRD because of reduced renal
elimination [54•].
CHGA Regulates Renal Function by Triggering
Weibel–Palade Body Exocytosis From Endothelial Cells
In twin pairs, the CHGA locus is a trans-quantitative trait
locus for determination of endothelin-1 (ET-1) secretion,
with maximal association in the CHGA promoter region, and
the CHGA protein itself triggers ET-1 release from human
umbilical vein endothelial cells [55]. Weibel-Palade bodies
are the storage granules of endothelial cells. They store and
release two principal molecules, von Willebrand factor and
P-selectin, and thus play a dual role in hemostasis and
inflammation. CHGA led to the release of ET-1 and indeed
global Weibel–Palade body exocytosis in cultured human
umbilical vein endothelial cells, and the secretory effect
mapped onto the amino-terminal (vasostatin) region of the
molecule. In addition, CHGA triggered secretion of ET-
1from glomerular capillary endothelial cells and TGF-β1
from co-cultured mesangial cells. In humans, plasma CHGA
correlated positively with ET-1 and negatively with the
glomerular filtration rate (GFR). GFR was highly heritable in
twin pairs, and common promoter haplotypes of CHGA
predicted the GFR trait value. In patients with progressive
hypertensive renal disease, a CHGA haplotype predicted the
rate of GFR decline. Thus CHGA seems to act through the
glomerular endothelium to regulate renal function as well as
progressive renal disease [56•].
An Experimental Animal Model: Elevated BP
After Targeted Chromogranin Gene Ablation
in the Mouse
Chga-/- (knockout) mice displayed extreme phenotypic
changes, including: decreased chromaffin granule size and
number; elevated BP; loss of diurnal BP variation; increased
left ventricular mass and cavity dimensions; decreased
adrenal catecholamine, neuropeptide Y (Npy), and ATP
contents; increased catecholamine/ATP ratio in the chromaf-
fin granule; and increased plasma catecholamine and Npy
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levels. Rescue of elevated BP to normalcy was achieved by
either exogenous catestatin replacement or humanization of
Chga-/- mice. Loss of the physiological “brake” catestatin in
Chga-/- mice, coupled with dysregulation of transmitter
storage and release, may act in concert to alter autonomic
control of the circulation in vivo, eventuating in hypertension
[3]. The syndrome could be “rescued” by BAC (bacterial
artificial chromosome) haplotype replacement of the human
CHGA gene into the mouse knockout strain genome [3, 57•].
The Chga-/- mouse displays widespread derangements in
autonomic function, both sympathetic and parasympathetic
[58•], including diminished baroreceptor sensitivity to both
high-pressure and low-pressure stimuli and diminished heart
rate variability [59•]; each of these can be rescued by
replacement of the catestatin (catecholamine release inhibitory)
fragment of CHGA.
Later studies indicated that the relationship of the Chga
gene to BP may be even more complex, with a biphasic (or
U-shaped) dose/response curve for Chga gene copy number
and basal BP [57•] and parallel changes in adrenal
catecholamine storage and release. In this transgenic model,
titration of CHGA gene copy number was enabled by BAC
haplotype replacement and targeted breeding.
Finally, loss of pancreastatin in the Chga-/- mouse has
predictable metabolic consequences, including heightened
sensitivity of glucose disposal to endogenous or exogenous
insulin [60•, 61•]. The insulin-hypersensitive state is
reversed by replacement of the dysglycemic pancreastatin
fragment of CHGA [61•].
Similarly, Chgb-/- (knockout) mice display substantially
higher SBP and DBP (by ∼20/∼18 mm Hg) than Chgb+/+
mice [62•]. These mice have 36% less adrenomedullary
epinephrine when compared to wild-type mice, whereas the
norepinephrine content is similar. This decrease is not due
to a lower frequency of exocytotic events, but rather to less
secretion per quantum (∼30%) measured by amperometry;
amperometric spikes exhibit a slower ascending phase but a
normal decaying phase [63]. Chgb-/- animals display some,
but not all, hallmarks of human type 2 diabetes. Stimulated
secretion of insulin, glucagon, and somatostatin is reduced
in Chgb-/- islets, in parallel with somewhat impaired
glucose clearance and reduced insulin release, but normal
insulin sensitivity in vivo [64].
Conclusions
The major soluble core proteins in catecholamine storage
vesicles (CHGA, CHGB, and SCG2) play catalytic roles in
vesiculogenesis. Common genetic variants in these pro-
teins, especially CHGA 3′-UTR C+87T (rs7610), CHGB
promoter A-296C (rs236140) and A-261T (rs236141), and
SCG2 intronic variant G736A (rs1017448), seem to exert
functional and interactive effects, first on early, “interme-
diate,” or pathogenic phenotypes and finally on basal/
resting BP in the population, leading to risk of hyperten-
sion. SNP-by-SNP interactions, either local (haplotypes) or
distant, may also play roles in the progression of BP. These
results point to new molecular strategies for probing
autonomic control of the circulation and ultimately the
susceptibility to and pathogenesis of cardiovascular disease
states such as hypertension.
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